Compare FEIM & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEIM | BNTC |
|---|---|---|
| Founded | 1961 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.3M | 420.3M |
| IPO Year | 1994 | 2020 |
| Metric | FEIM | BNTC |
|---|---|---|
| Price | $46.15 | $12.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $42.50 | $27.67 |
| AVG Volume (30 Days) | 127.8K | ★ 173.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.95 | 80.94 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $69,811,000.00 | N/A |
| Revenue This Year | $5.52 | N/A |
| Revenue Next Year | $17.07 | N/A |
| P/E Ratio | $204.00 | ★ N/A |
| Revenue Growth | ★ 26.30 | N/A |
| 52 Week Low | $14.41 | $9.85 |
| 52 Week High | $61.47 | $17.15 |
| Indicator | FEIM | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 42.07 | 57.49 |
| Support Level | $45.65 | $11.30 |
| Resistance Level | $59.91 | $12.75 |
| Average True Range (ATR) | 4.97 | 0.72 |
| MACD | -0.03 | 0.22 |
| Stochastic Oscillator | 10.60 | 61.66 |
Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.